Kelun-Biotech – Talk Bio

Actionable Insights Powered by AI

Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates

5 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck, NECTIN4 gene, SKB571, TROP2

Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571

Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs

8 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck & Co., Oncology Pipeline

Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline